PsychedelicNewsBreaks

TuesdayJan 04, 2022 2:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones to revolutionize mental health care. Among these, the company recently secured a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital. The hospital is part of Northwell Health, the largest health care system in New York State, and serves marginalized communities on the Upper East Side of Manhattan. Lenox Hill is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. A recent article quotes Cybin Chief Clinical Officer Dr. Alex…

Continue Reading

ThursdayDec 30, 2021 11:51 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year. It offers a glimpse into achievements to date, and what stakeholders can anticipate in the last quarter of the 2021 financial year and for the 2022 calendar year,” reads a recent article. “Most notably, Mydecine…

Continue Reading

TuesdayDec 28, 2021 1:42 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s…

Continue Reading

MondayDec 27, 2021 12:40 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Flagship Event Provides Pioneering Insights into Business, Psychedelics, Overall Wellness

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, held the Meet Delic Conference in November in Las Vegas, Nevada. The event, which featured over 60 thought leaders, medical professionals and wellness advocates, drew more than 2,500 attendees, becoming the largest psychedelic wellness and business conference in the world. “The Meet Delic conference aimed to raise awareness of the science-backed benefits of psychedelics and business opportunities inherent to the sector and the mainstream and larger community. The event featured dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations, in addition to one of the world’s largest…

Continue Reading

WednesdayDec 22, 2021 11:07 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with Maya. The two companies plan to co-develop a novel digital therapeutics (DTx) platform, which would allow Mydecine to enhance treatment effectiveness by pairing the DTx with its existing digital health platform, Mindleap Health, alongside its medication-based treatments to create a trifecta approach. “The technology integration of the two software platforms is aimed at enhancing Mindleap’s medical capabilities to more quickly and efficiently develop a personalized prescription-based digital…

Continue Reading

WednesdayDec 22, 2021 9:54 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in…

Continue Reading

TuesdayDec 21, 2021 11:50 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two premier events: the 11th annual LifeSci Partners Annual Corporate Access Event and the H.C. Wainwright Bioconnect Conference. Cybin CEO Doug Drysdale will participate in both upcoming virtual investor events. At the LifeSci Partners event, scheduled for Jan. 5–7, 2021, Drysdale will be involved in a panel discussion titled “Psychedelics: More Than Just a Trip.” The panel is slated for Wednesday, Jan. 5, at 10 a.m. ET. At the H.C. Wainwright Bioconnect Conference, Drysdale willparticipate in a fireside chat, which is scheduled…

Continue Reading

MondayDec 20, 2021 2:18 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine… The agreement gives the company’s medical and scientific research teams the resources needed to explore things…

Continue Reading

FridayDec 17, 2021 2:26 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research…

Continue Reading

ThursdayDec 16, 2021 12:58 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Co-Founder, CEO Featured on ‘Gamechangers LIVE’

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Delic’s CEO and Co-Founder Matt Stang joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss his background in the alternative drugs sector, the groundswell of clinical and regulatory developments relating to psychedelics and how Delic is supporting those advancements through its portfolio of…

Continue Reading